Indications: Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration Resistant Prostate Cancer (mCRPC) ,Higher Risk Myelodysplastic Syndrome (HR-MDS)
Drug: Eltanexor

Please visit clinicaltrials.gov for more information about this study

This trial is for eltanexor.

Rights

Drug: Eltanexor / Combination study expected to start in 2020.

Phase IPhase IIPhase III
Phase I
Phase II
Phase III